tiprankstipranks

Ravi Viswanathan Insider Profile

4 Followers
Ravi Viswanathan, Ten Percent Owner at Tesaro, holds 6.35M shares in Elastic (Ticker: ESTC), holds 94.98M shares in Adaptimmune Therapeutics (Ticker: ADAP), holds 18.70M shares in AVEO Pharma (Ticker: AVEO).
tipranks
Ravi Viswanathan

Ravi Viswanathan
Tesaro (TSRO)
Ten Percent Owner

Ranked #17,806 out of 98,564 Corporate Insiders

Profitable Transactions

33%
13 out of 40 Profitable Transactions

Average Return

+3.80%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$843M
77.27%
12.84%
4.67%
2.95%
2.28% Others
A breakdown of Ravi Viswanathan's holdings

Insider Roles

Elastic
(ESTC)
Ten Percent Owner
Adaptimmune Therapeutics
(ADAP)
Ten Percent Owner
Ardelyx
(ARDX)
Ten Percent Owner
Regulus
(RGLS)
Ten Percent Owner
+6 other positions
Roles that Ravi Viswanathan holds in companies

Most Profitable Insider Trade

Stock:
Achaogen
(AKAOQ)
Rating:Informative Buy
Date:Jun 07, 2016 - Jun 07, 2017
Return:+423.70%
The most profitable trade made by Ravi Viswanathan

Ravi Viswanathan's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
TSRO
Tesaro
Mar 06, 2018
Informative Buy
8.35M
$781.13M
Adaptimmune Therapeutics
Sep 10, 2018
Ten Percent Owner
Informative Buy
24.90M
$108.28M
AVEO
AVEO Pharma
Aug 22, 2018
Informative Buy
1.50M
$280.47M
AKAOQ
Achaogen
Dec 19, 2016
Informative Buy
6.75M
$117.88K
CASC
Cascadian Therapeutics
Mar 13, 2018
Uninformative Sell
$0.00
Regulus
Jul 31, 2017
Ten Percent Owner
Informative Buy
$24.84M
Appian
Feb 15, 2018
Ten Percent Owner
Uninformative Buy
$55.73K
Synlogic
Jan 26, 2018
Ten Percent Owner
Uninformative Buy
4.00M
$8.08M
SURF
Surface Oncology
Apr 23, 2018
Uninformative Buy
$3.54M
MULE
Mulesoft Inc
May 09, 2018
Uninformative Sell
$0.00
Elastic
Oct 10, 2018
Ten Percent Owner
Uninformative Buy
$651.49M
Arca Biopharma
Feb 27, 2018
Ten Percent Owner
Informative Sell
730.10K
$0.00
Ardelyx
May 30, 2018
Ten Percent Owner
Uninformative Buy
3.33M
$39.39M
TRACON Pharmaceuticals
Mar 27, 2018
Ten Percent Owner
Informative Buy
1.91M
$6.41M
Box
Jan 22, 2015
Ten Percent Owner
Informative Buy
$4.44M
~DERM
Dermira
Oct 08, 2014
Uninformative Buy
$65.68M
LOXO
Loxo Oncology
Aug 06, 2014
Uninformative Buy
$419.91M
~HIVE
Aerohive Networks
Apr 03, 2014
Uninformative Buy
$20.75M
CRCM
Care
Nov 08, 2017
Uninformative Buy
$33.85M
MM
Millennial Media
Oct 30, 2012
Informative Sell
21.47M
$14.34M
EPZM
Epizyme
Jan 12, 2016
Informative Buy
10.00M
$9.20M
ROKA
Sorrento Tech Inc
Jul 22, 2014
Uninformative Buy
$2.09M
Workday
Apr 11, 2013
Ten Percent Owner
Uninformative Buy
$200.58K
CLVSQ
Clovis Oncology
Jun 05, 2013
Uninformative Buy
$5.75
OMTH
Omthera
List of latest transactions for each holding click on a transaction to see Ravi Viswanathan's performance on stock

Ravi Viswanathan insider profile FAQ

What is the percentage of profitable transactions made by Ravi Viswanathan?
The percentage of profitable transactions made by Ravi Viswanathan is 33%.
    What is the average return per transaction made by Ravi Viswanathan?
    The average return per transaction made by Ravi Viswanathan is 3.80%.
      What stocks does Ravi Viswanathan hold?
      Ravi Viswanathan holds: TSRO, ADAP, AVEO, AKAOQ, CASC, RGLS, APPN, SYBX, SURF, MULE, ESTC, ABIO, ARDX, TCON, BOX, ~DERM, LOXO, ~HIVE, CRCM, MM, EPZM, ROKA, WDAY, CLVSQ, OMTH stocks.
        What was Ravi Viswanathan’s latest transaction?
        Ravi Viswanathan latest transaction was an Uninformative Buy of ―.
          What was Ravi Viswanathan's most profitable transaction?
          Ravi Viswanathan’s most profitable transaction was an Informative Buy of AKAOQ stock on June 7, 2016. The return on the trade was 423.70%.
            What is Ravi Viswanathan's role in Tesaro?
            Ravi Viswanathan's role in Tesaro is Ten Percent Owner.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.